129 related articles for article (PubMed ID: 16360440)
1. Frequency and clinicopathologic correlates of ErbB1, ErbB2, and ErbB3 immunoreactivity in urothelial tumors of upper urinary tract.
Tsai YS; Tzai TS; Chow NH; Wu CL
Urology; 2005 Dec; 66(6):1197-202. PubMed ID: 16360440
[TBL] [Abstract][Full Text] [Related]
2. [The expression of p53 and c-erb-2 in transitional cell carcinoma of the kidney pelvis and ureter and its relation to tumor progression and survival].
Fontana LO; García García F; Arcas Martínez Salas I; García Ligero J; Tomás Ros M; Rico Galiano JL; Sempere Gutiérrez A; Canteras Jordana M
Arch Esp Urol; 2002 Sep; 55(7):792-6. PubMed ID: 12380307
[TBL] [Abstract][Full Text] [Related]
3. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder.
Chow NH; Chan SH; Tzai TS; Ho CL; Liu HS
Clin Cancer Res; 2001 Jul; 7(7):1957-62. PubMed ID: 11448910
[TBL] [Abstract][Full Text] [Related]
4. Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3.
Chen X; Yeung TK; Wang Z
Biochem Biophys Res Commun; 2000 Nov; 277(3):757-63. PubMed ID: 11062025
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for intravesical recurrence following urothelial carcinoma of the upper urinary tract: no relationship to the mode of surgery.
Koda S; Mita K; Shigeta M; Usui T
Jpn J Clin Oncol; 2007 Apr; 37(4):296-301. PubMed ID: 17513309
[TBL] [Abstract][Full Text] [Related]
6. MUC4 and ErbB2 expression in squamous cell carcinoma of the upper aerodigestive tract: correlation with clinical outcomes.
Weed DT; Gomez-Fernandez C; Yasin M; Hamilton-Nelson K; Rodriguez M; Zhang J; Carraway KL
Laryngoscope; 2004 Aug; 114(8 Pt 2 Suppl 101):1-32. PubMed ID: 15284539
[TBL] [Abstract][Full Text] [Related]
7. Prognostic relevance of prothymosin-alpha expression in human upper urinary tract transitional cell carcinoma.
Jou YC; Tung CL; Tsai YS; Shen CH; Syue-Yi C; Shiau AL; Tsai HT; Wu CL; Tzai TS
Urology; 2009 Oct; 74(4):951-7. PubMed ID: 19679339
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of apoptosis-related markers in urothelial cancer of the upper urinary tract.
Jeong IG; Kim SH; Jeon HG; Kim BH; Moon KC; Lee SE; Lee E
Hum Pathol; 2009 May; 40(5):668-77. PubMed ID: 19157504
[TBL] [Abstract][Full Text] [Related]
9. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.
Spector NL; Xia W; Burris H; Hurwitz H; Dees EC; Dowlati A; O'Neil B; Overmoyer B; Marcom PK; Blackwell KL; Smith DA; Koch KM; Stead A; Mangum S; Ellis MJ; Liu L; Man AK; Bremer TM; Harris J; Bacus S
J Clin Oncol; 2005 Apr; 23(11):2502-12. PubMed ID: 15684311
[TBL] [Abstract][Full Text] [Related]
10. Expression of cyclooxygenase-2 and EP4 receptor in transitional cell carcinoma of the upper urinary tract.
Miyata Y; Kanda S; Nomata K; Eguchi J; Kanetake H
J Urol; 2005 Jan; 173(1):56-60. PubMed ID: 15592025
[TBL] [Abstract][Full Text] [Related]
11. ErbB receptors and fatty acid synthase expression in aggressive head and neck squamous cell carcinomas.
Silva SD; Cunha IW; Younes RN; Soares FA; Kowalski LP; Graner E
Oral Dis; 2010 Nov; 16(8):774-80. PubMed ID: 20604875
[TBL] [Abstract][Full Text] [Related]
12. Expression of Ki-67 and COX-2 in patients with upper urinary tract urothelial carcinoma.
Jeon HG; Jeong IG; Bae J; Lee JW; Won JK; Paik JH; Kim HH; Lee SE; Lee E
Urology; 2010 Aug; 76(2):513.e7-12. PubMed ID: 20573388
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of hypoxia-inducible factor-1alpha predicts an unfavorable outcome in urothelial carcinoma of the upper urinary tract.
Ke HL; Wei YC; Yang SF; Li CC; Wu DC; Huang CH; Wu WJ
Int J Urol; 2008 Mar; 15(3):200-5. PubMed ID: 18304212
[TBL] [Abstract][Full Text] [Related]
14. MUC4 and ERBB2 expression in major and minor salivary gland mucoepidermoid carcinoma.
Weed DT; Gomez-Fernandez C; Pacheco J; Ruiz J; Hamilton-Nelson K; Arnold DJ; Civantos FJ; Zhang J; Yasin M; Goodwin WJ; Carraway KL
Head Neck; 2004 Apr; 26(4):353-64. PubMed ID: 15054739
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for intravesical recurrence after surgical management of transitional cell carcinoma of the upper urinary tract.
Terakawa T; Miyake H; Muramaki M; Takenaka A; Hara I; Fujisawa M
Urology; 2008 Jan; 71(1):123-7. PubMed ID: 18242379
[TBL] [Abstract][Full Text] [Related]
16. Different patterns of expression of the erbB family of receptor tyrosine kinases in common nevi, dysplastic nevi, and primary malignant melanomas: an immunohistochemical study.
Feinmesser M; Veltman V; Morgenstern S; Tobar A; Gutman H; Kaganovsky E; Tzabari C; Sulkes J; Okon E
Am J Dermatopathol; 2010 Oct; 32(7):665-75. PubMed ID: 20559114
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of lymphovascular invasion in upper urinary tract urothelial cancer.
Akao J; Matsuyama H; Yamamoto Y; Hara T; Kawai Y; Sakano S; Ohmi C; Gondo T; Naito K
BJU Int; 2008 Aug; 102(5):572-5. PubMed ID: 18485032
[TBL] [Abstract][Full Text] [Related]
18. Location of the primary tumor is not an independent predictor of cancer specific mortality in patients with upper urinary tract urothelial carcinoma.
Isbarn H; Jeldres C; Shariat SF; Liberman D; Sun M; Lughezzani G; Widmer H; Arjane P; Pharand D; Fisch M; Graefen M; Montorsi F; Perrotte P; Karakiewicz PI
J Urol; 2009 Nov; 182(5):2177-81. PubMed ID: 19758662
[TBL] [Abstract][Full Text] [Related]
19. Behavior of urothelial carcinoma with respect to anatomical location.
Catto JW; Yates DR; Rehman I; Azzouzi AR; Patterson J; Sibony M; Cussenot O; Hamdy FC
J Urol; 2007 May; 177(5):1715-20. PubMed ID: 17437794
[TBL] [Abstract][Full Text] [Related]
20. Controlled activation of ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: implications for progression of ErbB2-overexpressing tumors.
Zhan L; Xiang B; Muthuswamy SK
Cancer Res; 2006 May; 66(10):5201-8. PubMed ID: 16707444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
